Cognivia Shareholder Update: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Season1}} | |||
This is the [[Cognivia]] Shareholder Update presented at the begining of 269 to shareholders. We acquired it by way of [[Helix Hesh]], with some help from [[Tippy]]. | This is the [[Cognivia]] Shareholder Update presented at the begining of 269 to shareholders. We acquired it by way of [[Helix Hesh]], with some help from [[Tippy]]. | ||
Latest revision as of 19:52, 13 March 2007
|
PERPLEX CITY, SEASON ONE |
This is the Cognivia Shareholder Update presented at the begining of 269 to shareholders. We acquired it by way of Helix Hesh, with some help from Tippy.
cnv
c o g n i v i a
Shareholder Update
March 269
cnv
c o g n i v i a
Shareholder Update
March 269
a brighter future
Cognivia is leaner, fitter and better placed than ever. Over the past financial year, our share of the cognitive enhancement retail market increased from 68% to 69%, leading to an increase in turnover of 3.2%.
Coupled with our internal efficiency programme and streamlined distribution network, this gave us a 4.7% rise in profits (before exceptional items).
Progress in mind
Our investments in AI continue to produce extremely promising results. Agilon is on the verge of completing its new City Behavioural Model, which will prove invaluable to anyone wishing to predict citizens' reactions to a huge variety of stimuli – from natural disasters to marketing campaigns.
Completing the picture
In prosthetics, we're forging ahead in our development of nanotechnology. Within the year, we expect to have completed the core work on our neural scanner, which will allow us to map and replicate the networks of any part of the brain. It will soon be possible to scan a healthy brain in its entirety and, if it is damaged in later life, to recreate a prosthesis of the damaged region.
The winning formula
This year, we also continued our successful association with the PCAG. The exposure this gives Cognivia is a key factor in our domination of the market, and we've been working hard to maintain our position as the PCAG's partner of choice.
To keep up with the latest enhancement and concealment techniques, our biodata scans have been upgraded to include a full genetic profile, highlighting any signs of gene therapy. And as cerebral prosthetics become more and more sophisticated, we've developed new methods for detecting and disabling nanotechnology.
Shareholder Update
March 269
cnv
c o g n i v i a
evolution, accelerated
For millions of years, life has been a missed opportunity. Generations of human beings have been able to access only a fraction of their mental capacity, never reaching their full potential.
In the past twenty years, Cognivia has taken the human mind to new levels. The< ability to enhance our own faculties has heralded the start of a new evolutionary era. Mankind has entered the Mind Age.
The next generation
And now, we're preparing to take the next step in that evolution. Ceretin 6 is in its final test phase, having already shown significantly improved performance over the current generation of Ceretin.
Very soon, Cognivia customers will have the opportunity to be even faster, sharper and more alert. Imagine the difference it could make to your life.
Natural selection
Before we move forward in our development, we want to be absolutely sure that we're heading in the right direction. That's why we're taking a little more time to perfect Ceretin 6, making certain that we understand any test anomalies.
The testing phase is designed to highlight issues as early as possible. It is doing exactly that. Rather than worry about the extended test process, we should be glad that any imperfections have been detected at a stage when we can study and correct them.
The human race has waited millions of years to reach this point. We can afford to spend a few more months sharpening our future.
Shareholder Update
March 269
cnv
c o g n i v i a
thinking ahead
This has been a great year for Cognivia, in the face of challenging conditions.
Not only have we produced our best ever financial results, but we've also laid the foundations for future success.
All our shareholders can feel confident that their investment will continue to grow, as we work to improve the lives of our citizens in a financially responsible manner.
Proof copies of the forthcoming C6 research paper will be available to CE professionals in April 269.
For further details, please contact us at media@cognivia.com or log into your secure account.
